Trial Profile
Apatinib With Postoperative Adjuvant Chemotherapy for Operable Colorectal Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 31 Jan 2020 Planned initiation date changed from 1 Aug 2017 to 1 Mar 2020.
- 31 Jan 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 10 Jan 2018 Planned End Date changed from 30 Apr 2023 to 1 Mar 2023.